Skip to main content

Table 1 Baseline clinical characteristics

From: The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome

 

Statin group (n = 52)

Combination group (n = 52)

p

AMI/ UA (n)

27/25

30/22

0.144

Gender (male/female)

16/36

20/32

0.101

Age (years)

60 ± 6

59 ± 8

0.356

Body mass index (kg/m2)

23.48 ± 1.67

23.94 ± 2.09

0.233

Systolic blood pressure (mmHg)

131 ± 11

133 ± 12

0.195

Diastolic blood pressure (mmHg)

76 ± 8

75 ± 9

0.471

Fasting blood glucose (mmol/L)

5.45 ± 0.66

5.62 ± 0.95

0.263

ALT (u/L)

31.57 ± 21.06

29.08 ± 16.67

0.688

Cr (μmol/L)

87.4 ± 21.67

86.03 ± 18.84

0.728

CK (u/L)

86.01 ± 22.91

87.13 ± 46.38

0.875

TG (mmol/L)

1.97 ± 1.02

1.91 ± 0.87

0.740

TC (mmol/L)

4.85 ± 0.90

4.92 ± 0.83

0.644

LDL-C (mmol/L)

3.00 ± 0.43

3.04 ± 0.46

0.686

HDL-C (mmol/L)

0.89 ± 0.22

0.93 ± 0.14

0.317

Apo A5 (ng/ml)

49.49 ± 1.59

49.50 ± 2.48

0.980

hs-CRP (mg/L)

3.97 ± 3.52

3.89 ± 2.96

0.904

  1. Note: AMI acute myocardial infarction, UA unstable angina, ALT alanine aminotransferase, Cr creatinine, CK creatine kinase, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ApoA5 apolipoprotein A5, hs-CRP high-sensitivity C-reactive protein.